Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BAX | Q07812 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592371 | 0.86 | KMT2A (0.44) | LMNAKMT2APOLB | |
| SCHEMBL3640809 | 0.85 | POLB (0.41) | LMNAKMT2APOLB | |
| SCHEMBL21556286 | 0.82 | DDR1 (0.40) | DDR1HTR6 | |
| SCHEMBL8136737 | 0.82 | POLB (0.39) | LMNAKMT2APOLB | |
| SCHEMBL1592443 | 0.81 | POLB (0.48) | HIF1ALMNAKMT2AHTR6POLB | |
| SCHEMBL1592431 | 0.81 | THRB (0.46) | LMNAKMT2AHSD17B10HTR6POLB | |
| SCHEMBL8134771 | 0.81 | POLB (0.54) | LMNAKMT2APOLB | |
| SCHEMBL1592421 | 0.80 | CA12 (0.41) | POLB | |
| SCHEMBL1592514 | 0.80 | CHEK1 (0.38) | PDE10ACACNA2D1KMT2ACHEK1 | |
| SCHEMBL20880380 | 0.80 | MEN1 (0.46) | LMNAKMT2AHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CDKN1A, CDC25C, DDB1 | HIF1A 750/4885PDE10A 4217/4885DDR1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.